

Listing of Claims:

1. (previously presented) A composition comprising an agent effective to elicit an immunogenic response to alpha-synuclein and an adjuvant that is pharmaceutically acceptable for human administration, wherein the adjuvant is selected from the group consisting of QS21, monophosphoryl lipid, alum, CpG, GM-CSF and M-CSF, wherein the agent is alpha-synuclein or an immunogenic fragment thereof.
2. (canceled)
3. (previously presented) The composition of claim 1, wherein the agent is alpha-synuclein.
4. (previously presented) The composition of claim 1, wherein the agent is immunogenic alpha-synuclein fragment.
5. (previously presented) The composition of claim 4, wherein the agent is NAC.
6. (previously presented) The composition of any one of claims 1 or 3 - 5, wherein the agent is linked to a carrier molecule to form a conjugate.
- 7-53. (canceled)
54. (previously presented) The composition of claim 1, manufactured under good manufacturing practice conditions.
55. (previously presented) The composition of claim 1, wherein the agent is filter sterilized.